Evolution of the Average Target: Autolus Therapeutics plc

Evolution of the Average Target - Autolus Therapeutics plc

Evolution of the Target Price: Autolus Therapeutics plc

Evolution of the Target Price - Autolus Therapeutics plc

Changes in Analyst Recommendations: Autolus Therapeutics plc

817ac9a8fd0422d.jv4bevCx3S5OFPl2IyJ46dbFYGhoXzxBh0ZAo2mwGGo.5pprN7bluBYvbL8yUFJOmJWwOjpFG0x08zEzkjCEbQLFsXMXlYK_fQRcjg~c0921b45b182ab6086460487910574d8
03-31 Mizuho Cuts Price Target on Autolus Therapeutics to $10 From $12, Keeps Outperform Rating MT
01-13 Truist Adjusts Price Target on Autolus Therapeutics to $8 From $10, Maintains Buy Rating MT
01-13 Truist Cuts Price Target on Autolus Therapeutics to $8 From $10, Keeps Buy Rating MT
25-03-31 Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating MT
24-11-18 Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7 MT
24-11-15 Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13 MT
24-03-18 Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating MT
24-02-12 Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating MT
24-01-22 Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating MT
23-12-13 Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating MT
23-11-09 Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target MT
23-08-17 Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating MT
23-05-05 Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating MT
23-03-27 Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target MT
23-03-08 Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating MT
22-12-09 Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating MT
22-08-23 Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating MT
22-06-14 Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating MT
21-12-20 HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating MT
21-08-24 Autolus Therapeutics : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating MT
21-06-14 Autolus Therapeutics : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6 MT
21-05-06 Autolus Therapeutics : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating MT
21-03-10 Autolus Therapeutics : Redburn Downgrades Autolus Therapeutics to Neutral from Buy MT
21-01-29 Autolus Therapeutics : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24 MT
21-01-07 Autolus Therapeutics : HC Wainwright Adjusts Autolus Therapeutics' Price Target to $13 From $19, Keeps at Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+382.04%
+12.79%
+7.03%
+2.22%
+8.71%
+5.14%
+4.76%
+31.69%
-4.73%
+5.43%
Average +45.51%
Weighted average by Cap. +8.70%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.810USD
Average target price
8.725USD
Spread / Average Target
+382.04%
High Price Target
11.00USD
Spread / Highest target
+507.73%
Low Price Target
5.000USD
Spread / Lowest Target
+176.24%

Analyst Consensus Detail

Analyst consensus - Autolus Therapeutics plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Autolus Therapeutics plc
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock
  4. Consensus Autolus Therapeutics plc